2488-54-2

Usage

Type of compound

Organic compound

Structure

Contains a benzene ring substituted with a chlorine atom, a nitro group, and a difluoromethylsulfonyl group

Applications

a. Intermediate in the synthesis of pharmaceuticals
b. Intermediate in the synthesis of agrochemicals
c. Intermediate in the synthesis of dyes
d. Precursor in the production of specialty chemicals and other organic compounds

Chemical reactivity

Influenced by the difluoromethylsulfonyl group, making it a useful building block in organic synthesis

Stability

Enhanced by the difluoromethylsulfonyl group

Odor

Strong, unpleasant

Safety

Toxic and irritant properties; should be handled with care and proper safety protocols followed during handling and storage

Upstream product

• 2488-53-1 1-chloro-4-((difluoromethyl)sulfonyl)benzene 
• 106-54-7 p-Chlorothiophenol 
• 2488-66-6 1-chloro-4-[(difluoromethyl)sulfanyl]benzene 

Downstream Products

• 24933-35-5 (4-Aethylamino-3-amino-phenyl)-difluormethyl-sulfon 
• 55391-51-0 4-(Difluoro-methanesulfonyl)-2-nitro-phenylamine 
• 2673-02-1 3-{2-[5-(Difluoro-methanesulfonyl)-2-hexadecylsulfanyl-phenylcarbamoyl]-acetyl}-benzenesulfonyl fluoride 
• 2489-35-2 5-(Difluoro-methanesulfonyl)-2-hexadecylsulfanyl-phenylamine 
• 24933-34-4 (4-Aethylamino-3-nitro-phenyl)-difluormethyl-sulfon 
• 2488-55-3 4-(Difluoro-methanesulfonyl)-1-hexadecylsulfanyl-2-nitro-benzene 

Relevant academic research and scientific papers

Synthesis and in vitro antibacterial activity of 5-halogenomethylsulfonyl- benzimidazole and benzotriazole derivatives

A series of 5-halogenomethylsulfonylbenzimidazole and benzotriazole derivatives was synthesized as potential antibacterial agents. A new method of synthesis of benzimidazoles was developed. The antimicrobial activities of these compounds were tested against a series of reference and clinical strains. The reference strains include Gram-positive bacteria (S. aureus, S. epidermidis, B. subtilis, B. cereus, E. hirae, M. luteus) and Gram-negative rods (E. coli, P. vulgaris, P. aeruginosa, B. bronchiseptica). The clinical strains include six methicillin-resistant (MRSA) and two methicillin-sensitive (MSSA) S. aureus strains, one methicillin-resistant S. epidermidis, three E. faecalis and two E. faecium strains. Compound with trifluoromethyl- substituent at C-2 position (4) displayed significant antibacterial activities comparable with nitrofurantoin against four strains, and higher against Micrococcus luteus. MIC values for clinical Staphylococci strains (MRSA) were 12.5-25 μg/mL; for Enterococcus strains these values were 50-100 μg/mL. MIC values for reference and clinical strains of Staphylococcus and Enterococcus group were similar, respectively.